RTW Biotech Opportunities – executive interview

RTW Biotech Opportunities – executive interview

RTW Biotech Opportunities — 1 video in collection

More on this equity

Edison’s head of investment companies, Rob Murphy, met Roderick Wong, managing director of RTW Investments, to discuss RTW Biotech Opportunities (RTW Bio; ticker RTW/RTWG). Wong outlines RTW Bio’s outperformance versus its two biotech index benchmarks in 2023 and since the fund’s launch in October 2019. He also discusses his outlook for the biotech industry in 2024. Furthermore, Wong highlights RTW Bio’s acquisition of Arix Bioscience’s assets and the anticipated timeline for the deal to be completed. Finally, Wong reiterates his vision for RTW Bio and how it fits in with RTW Investments’ other funds.


You may also be interested in these:

Investment Companies

Take on trusts – July 2026

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.